ArticleMedComm2024

A pilot trial of neoadjuvant pyrotinib plus trastuzumab, dalpiciclib, and letrozole for triple-positive breast cancer.

Shiwen Huo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.